IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genesYukihide Momozawa, Judy H. Cho, Yurii S. Aulchenko et al.|Nature Communications|2018Cited by 252
Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort StudyVince Biemans, Frank Hoentjen, Andrea E. van der Meulen‐de Jong et al.|Journal of Crohn s and Colitis|2019Cited by 183
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE studyAnnick Moens, Marc Ferrante, C. Janneke van der Woude et al.|Alimentary Pharmacology & Therapeutics|2019Cited by 137
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentVince Biemans, C. Janneke van der Woude, Gerard Dijkstra et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 129
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s DiseaseMark Löwenberg, Geert D’Haens, Séverine Vermeire et al.|Gastroenterology|2019Cited by 127